Navigation Links
Inventive combination of research approaches identifies new target for treating leukemia
Date:10/5/2009

New research integrates sophisticated interdisciplinary approaches to solve a molecular mystery that may lead to alternative therapeutic strategies for acute myeloid leukemia (AML). The study, published by Cell Press in the October issue of the journal Cancer Cell, identifies a previously unrecognized AML target that responds well to pharmacological inhibition and may be an excellent candidate for use in future clinical trials.

AML is a type of blood cancer that disrupts normal blood cell production. "Long term survival for patients with AML remains poor despite dose-intensive chemotherapy regimens," explains senior study author, Dr. Kimberly Stegmaier from Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, and Children's Hospital Boston. "For older adults, long-term survival is dismal, and many older patients are unable to tolerate standard cytotoxic therapy." Unfortunately, identification of new treatment strategies has proven difficult as many potential targets are proteins that do not respond well to standard pharmacological methods.

Another challenge has been to unravel the molecular mechanisms associated with compounds that inhibit or reverse AML progression. Target identification is necessary for optimization of drug treatment. Dr. Stegmaier and colleagues had previously demonstrated that epidermal growth factor receptor (EGFR) inhibitors exhibited anti-AML activity. However, this finding was somewhat puzzling as EGFR is not expressed in AML. The researchers made use of sophisticated cross-disciplinary approaches to study gene expression (genomics) and protein structure and function (proteomics) to elucidate the molecular basis for the effect of EGFR inhibitors in AML.

Spleen tyrosine kinase (Syk) was identified as a target in AML. Syk is expressed in blood cells and is critical for proper blood cell differentiation. Recent research has implicated Syk in blood cancers, specifically lymphomas and leukemias. Genetic and pharmacological inactivation of Syk resulted in anti-AML activity in AML cell lines, primary patient samples and animal models of AML. Importantly, there are Syk inhibitors currently being tested in clinical trials.

These results identify Syk as a promising therapeutic target for treatment of AML. "With an orally available, well-tolerated Syk inhibitor currently in clinical development for other indications, our results should have immediate relevance for clinical testing of Syk inhibition in patients with AML," say Dr. Stegmaier. "Our study also validates the feasibility of integrating genetic and proteomic approaches to identify small molecules and their mechanisms of action."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Modern Health Care Economics is Driving Inventiveness in Delivery of Cancer Surgery and Management of Risk
2. Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
3. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
4. Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
5. More Sleep & Less Sex - A Losing Combination
6. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
7. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
8. Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus)
9. Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center is ... of time of female aging. The Julietâ„¢ procedure helps to reverse ... as leakage, laxity, itchiness and pain have reported real relief from these and other ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, a leading ... their clients' employee participation for their wellness initiatives. BeniComp clients experience nearly ... health plan with outcome-based deductible incentives. As a result, BeniComp clients have been ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is ... cereals and other plant-based foods, will introduce the first consumer product (a new breakfast ... Hesco/Dakota Organic Products. , The transitional designation means the cereal was made using at ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures , a national ... leading engineers at the American Society of Safety Engineers Conference in Atlanta, Georgia. ... , Engineers, speakers and exhibitors from more than 40 countries are scheduled to ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/24/2016)... , May 24, 2016   ... demonstrating non-inferiority in overall bowel cleansing and superiority in ... c leansing of the ... ) , Norgine B.V. today announced new positive ... PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology: